ResearcherHarvard UniversityActive in the last 2 years
Nilesh P. Talele
Matched on ORCID iD 0000-0003-2758-8599; OpenAlex author ID A5080818678. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 23
2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper
Papers 3
- IL-1β blockade prevents cardiotoxicity and improves the efficacy of immune checkpoint blockers and chemotherapy against pancreatic cancer in mice with obesity. Co-author DOI 10.1136/jitc-2024-011404↗
- Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Cancer Cells in Locally Advanced Pancreatic… Co-author DOI 10.1158/1078-0432.ccr-22-1630↗
- Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical… Co-author DOI 10.1001/jamaoncol.2019.0892↗
Closest collaborators
The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Rakesh K. Jain · 3 shared papers, 2019–2025 · strength 0.45
- Paper IL-1β blockade prevents cardiotoxicity and improves the efficacy of immune checkpoint blockers and chemotherapy against… DOI 10.1136/jitc-2024-011404↗
- Paper Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Can… DOI 10.1158/1078-0432.ccr-22-1630↗
- Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
- Dan Gabriel Duda · 3 shared papers, 2019–2025 · strength 0.45
- Paper IL-1β blockade prevents cardiotoxicity and improves the efficacy of immune checkpoint blockers and chemotherapy against… DOI 10.1136/jitc-2024-011404↗
- Paper Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Can… DOI 10.1158/1078-0432.ccr-22-1630↗
- Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
- Mikaël J. Pittet · 2 shared papers, 2023–2025 · strength 0.38
- Paper IL-1β blockade prevents cardiotoxicity and improves the efficacy of immune checkpoint blockers and chemotherapy against… DOI 10.1136/jitc-2024-011404↗
- Paper Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Can… DOI 10.1158/1078-0432.ccr-22-1630↗
- Dai Fukumura · 2 shared papers, 2023–2025 · strength 0.38
- Paper IL-1β blockade prevents cardiotoxicity and improves the efficacy of immune checkpoint blockers and chemotherapy against… DOI 10.1136/jitc-2024-011404↗
- Paper Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Can… DOI 10.1158/1078-0432.ccr-22-1630↗
- Theodore Sunki Hong · 2 shared papers, 2019–2023 · strength 0.21
- Paper Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Can… DOI 10.1158/1078-0432.ccr-22-1630↗
- Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
- Yves Boucher · 2 shared papers, 2019–2023 · strength 0.21
- Paper Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Can… DOI 10.1158/1078-0432.ccr-22-1630↗
- Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
- David P. Ryan · 2 shared papers, 2019–2023 · strength 0.21
- Paper Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Can… DOI 10.1158/1078-0432.ccr-22-1630↗
- Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
- Jennifer Yon-Li Wo · 2 shared papers, 2019–2023 · strength 0.21
- Paper Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Can… DOI 10.1158/1078-0432.ccr-22-1630↗
- Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
- Carlos F. Fernandez-del Castillo · 1 shared paper, 2023 · strength 0.14
- Mari A. Mino-Kenudson · 1 shared paper, 2023 · strength 0.14
- David Tsai Ting · 1 shared paper, 2019 · strength 0.06
- Jason Edward Faris · 1 shared paper, 2019 · strength 0.06
- Janet E. Murphy · 1 shared paper, 2019 · strength 0.06
- Carlos Fernández-del Castillo · 1 shared paper, 2019 · strength 0.06
- Lawrence Scott Blaszkowsky · 1 shared paper, 2019 · strength 0.06
- Motaz Qadan · 1 shared paper, 2019 · strength 0.06
- Cristina Rosa Ferrone · 1 shared paper, 2019 · strength 0.06
- Aparna R. Parikh · 1 shared paper, 2019 · strength 0.06
- Keith D. Lillemoe · 1 shared paper, 2019 · strength 0.06
- Eunice Lee Kwak · 1 shared paper, 2019 · strength 0.06
- Ryan David Nipp · 1 shared paper, 2019 · strength 0.06
- Ryan Bruce Corcoran · 1 shared paper, 2019 · strength 0.06
- Colin D. Weekes · 1 shared paper, 2019 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.